Trojan horses: Drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 42-49

  Pendergraft, William F ^a,b,c   Niles, John L ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Division of Nephrology   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antineutrophil cytoplasmic autoantibody; cocaine; hydralazine; minocycline; propylthiouracil

Indexed keywords

ALLOPURINOL; COCAINE; HYDRALAZINE; LEVAMISOLE; MINOCYCLINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENICILLAMINE; PROPYLTHIOURACIL; SALAZOSULFAPYRIDINE; THIAMAZOLE;

ACNE VULGARIS; ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; ARTHRALGIA; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLON CANCER; COMPARATIVE STUDY; DIALYSIS; DRUG WITHDRAWAL; FEVER; GLOMERULONEPHRITIS; GRANULOMATOSIS; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUPUS LIKE SYNDROME; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PHYSICIAN; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TICK BORNE DISEASE; URINALYSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COCAINE; COCAINE-RELATED DISORDERS; DRUG CONTAMINATION; HUMANS; HYDRALAZINE; LEVAMISOLE; MINOCYCLINE; PROPYLTHIOURACIL;

EID: 84890203823     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000014     Document Type: Review

References (67)

1. Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol 2013; 8:139-160.
2. Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318:1651-1657.
3. Niles JL, McCluskey RT, Ahmad MF, Arnaout MA. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 1989; 74:1888- 1893.
4. Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphatebinding protein in the lysosomes of normal human neutrophils. J Clin Investig 1989; 84:1577-1587.
5. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367:214-223.
6. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
7. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
8. Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: A clinical and pathological review. Neth J Med 2012; 70:12-17.
9. Choi HK, Merkel PA, Niles JL. ANCA-positive vasculitis associated with allopurinol therapy. Clin Exp Rheumatol 1998; 16:743-744.
10. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthr Rheum 2000; 43:405- 413.
11. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36:130-147.
12. Miura N, Aoyama R, Kitagawa W, et al. Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment. Clin Nephrol 2009; 71:74-79.
13. Denissen NH, Peters JG, Masereeuw R, Barrera P. Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis? Scand J Rheumatol 2008; 37:72-74.
14. Choi HK, Slot MC, Pan G, et al. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthr Rheum 2000; 43:2488-2492.
15. Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol 1998; 10:45-50.
16. Chang S, Feigenbaum H, Dillon J. Subxiphoid echocardiography. Chest 1975; 68:233-235.
17. Bienaime F, Clerbaux G, Plaisier E, et al. D-Penicillamine-induced ANCAassociated crescentic glomerulonephritis in Wilson disease. Am J Kidney Dis 2007; 50:821-825.
18. Kandler MR, Mah GT, Tejani AM, et al. Hydralazine for essential hypertension. Cochrane Database Syst Rev 2011; 11:CD004934.
19. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62 (16):e147-239.
20. Chang C, Gershwin ME. Drug-induced lupus erythematosus: Incidence, management and prevention. Drug Safety 2011; 34:357-374.
21. Marina VP, Malhotra D, Kaw D. Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: A rare clinical presentation. Int Urol Nephrol 2012; 44:1907-1909.
22. Kalra A, Yokogawa N, Raja H, et al. Hydralazine-induced pulmonary-renal syndrome: A case report. Am J Ther 2012; 19:e136-138.
23. Dobre M, Wish J, Negrea L. Hydralazine-induced ANCA-positive pauciimmune glomerulonephritis: A case report and literature review. Ren Fail 2009; 31:745-748.
24. Sangala N, Lee RW, Horsfield C, Goldsmith DJ. Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: A timely reminder of an old foe. Int Urol Nephrol 2010; 42:503-506.
25. Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: Comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol 2009; 19:338-347.
26. Relling MV. Polymorphic drug metabolism. Clin Pharm 1989; 8:852-863.
27. Russell GI, Bing RF, Jones JA, et al. Hydralazine sensitivity: Clinical features, autoantibody changes and HLA-DR phenotype. Q J Med 1987; 65:845- 852.
28. Ramsay LE, Silas JH, Ollerenshaw JD, et al. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension? Eur J Clin Pharmacol 1984; 26:39-42.
29. Alcorta D, Preston G, Munger W, et al. Microarray studies of gene expression in circulating leukocytes in kidney diseases. Exp Nephrol 2002; 10:139-149.
30. Yang JJ, Preston GA, Alcorta DA, et al. Expression profile of leukocyte genes activated by antineutrophil cytoplasmic autoantibodies (ANCA). Kidney Int 2002; 62:1638-1649.
31. Yang JJ, Pendergraft WF, Alcorta DA, et al. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibodyassociated glomerulonephritis. J Am Soc Nephrol 2004; 15:2103-2114.
32. Ciavatta DJ, Yang J, Preston GA, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Investig 2010; 120:3209-3219.
33. De la Cruz-Hernandez E, Perez-Plasencia C, Perez-Cardenas E, et al. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep 2011; 25:399-407.
34. Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 2013; 13:379- 399.
35. Kircik LH. Doxycycline and minocycline for the management of acne: A review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol 2010; 9:1407-1411.
36. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthr Rheum 2001; 44:2235-2241.
37. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthr Care Res 2012; 64:625-639.
38. El-Hallak M, Giani T, Yeniay BS, et al. Chronic minocycline-induced autoimmunity in children. J Pediatr 2008; 153:314-319.
39. Chang C, Gershwin ME. Drugs and autoimmunity: A contemporary review and mechanistic approach. J Autoimmun 2010; 34:J266-J275.
40. Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst Rev 2012; 8:CD002086.
41. Kermani TA, Ham EK, Camilleri MJ, Warrington KJ. Polyarteritis nodosa-like vasculitis in association with minocycline use: A single-center case series. Semin Arthr Rheum 2012; 42:213-221.
42. Tabriziani H, Wilcox CS, Gilbert ON, Lipkowitz MS. Minocycline-induced renal polyarteritis nodosa. Br Med J Case Rep; 2012. doi: 10.1136/bcr-2012- 006503.
43. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122:81-89.
44. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352:905-917.
45. Bukhari M. Drug-induced rheumatic diseases: A review of published case reports from the last two years. Curr Opin Rheumatol 2012; 24:182-186.
46. Wan P, Zhao X, Hunasehally RY, et al. Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide. Int J Dermatol 2012; 51:345- 348.
47. Chen M, Gao Y, Guo XH, Zhao MH. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nature Rev Nephrol 2012; 8:476-483.
48. Liu YC, Huang CM. Images in emergency medicine. Woman with painful purpura: Propylthiouracil-related ANCA-positive vasculitis. Ann Emerg Med 2012; 60:260-268.
49. Tetikkurt C, YuruyenM, Tetikkurt S, et al. Propylthiouracil-induced lupus-like or vasculitis syndrome. Multidiscip Respir Med 2012; 7:14.
50. Kimura M, Seki T, Ozawa H, et al. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Endocr J 2013; 60:383-388.
51. Ayturk S, Demir MV, Yaylaci S, Tamer A. Propylthiouracil induced leukocytoclastic vasculitis: A rare manifestation. Ind J Endocrinol Metab 2013; 17:339-340.
52. Cao X, Lin W. Clinical study of renal impairment in patients with propylthiouracil- induced small-vessel vasculitis and patients with primary ANCA-associated small-vessel vasculitis. Exp Ther Med 2013; 5:1619-1622.
53. Chen YX, Zhang W, Chen XN, et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis versus primary ANCA-associated renal vasculitis: A comparative study. J Rheumatol 2012; 39:558-563.
54. Choi HK, Merkel PA, Tervaert JW, et al. Alternating antineutrophil cytoplasmic antibody specificity: Drug-induced vasculitis in a patient with Wegener's granulomatosis. Arthr Rheum 1999; 42:384-388.
55. Waldhauser L, Uetrecht J. Antibodies to myeloperoxidase in propylthiouracilinduced autoimmune disease in the cat. Toxicology 1996; 114:155-162.
56. Nakazawa D, Tomaru U, Suzuki A, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps. Arthr Rheum 2012; 64:3779-3787.
57. Pomara C, Cassano T, D'Errico S, et al. Data available on the extent of cocaine use and dependence: Biochemistry, pharmacologic effects and global burden of disease of cocaine abusers. Curr Med Chem 2012; 19:5647- 5657.
58. Wolford A, McDonald TS, Eng H, et al. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: A case for reactive metabolite(s) involvement. Drug Metab Dispos 2012; 40:1067-1075.
59. Chang A, Osterloh J, Thomas J. Levamisole: A dangerous new cocaine adulterant. Clin Pharmacol Ther 2010; 88:408-411.
60. Zhu NY, Legatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med 2009; 150:287-289.
61. Graf J, Lynch K, Yeh CL, et al. Purpura, cutaneous necrosis, and antineutrophil cytoplasmic antibodies associated with levamisole-adulterated cocaine. Arthr Rheum 2011; 63:3998-4001.
62. Buchanan JA, Lavonas EJ. Agranulocytosis and other consequences due to use of illicit cocaine contaminated with levamisole. Curr Opin Hematol 2012; 19:27-31.
63. McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol 2011; 6:2799-2805.
64. Graf J. Rheumatic manifestations of cocaine use. Curr Opin Rheumatol 2013; 25:50-55.
65. Espinoza LR, Perez Alamino R. Cocaine-induced vasculitis: Clinical and immunological spectrum. Curr Rheumatol Rep 2012; 14:532-538.
66. Trimarchi M, Bussi M, Sinico RA, et al. Cocaine-induced midline destructive lesions: An autoimmune disease? Autoimmun Rev 2013; 12:496-500.
67. Lazareth H, Peytavin G, Polivka L, Dupin N. The hairy-print for levamisoleinduced vasculitis. Br Med J Case Rep 2012. doi: 10. 1136/bcr-2012- 006602. Kidney Diseases